Opioid Use Disorder Clinical Trial
— THC-MMTOfficial title:
Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy for Individuals Living With Opioid Use Disorder: A Phase II, Placebo-controlled, Blinded, Pilot Study to Assess Safety and Feasibility (THC-MMT)
This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol (THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist Therapy (OAT) for individuals with opioid use disorder (OUD) in a community setting.
Status | Not yet recruiting |
Enrollment | 24 |
Est. completion date | September 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years and older |
Eligibility | Inclusion Criteria: 1. Individuals of at least 25 years of age or older; 2. Diagnosed with OUD as per DSM-5 criteria; 3. Initiated or re-initiated methadone-based OAT within the past 30 days prior to study entry; 4. Cannabis-use experienced, defined as having used any amount of cannabis in the six months prior to the screening visit; 5. Willing to only use study-provided cannabis as directed by study protocol, including abstention from non-study cannabis and cannabinoids; 6. Agree to keep all study medication stored in a secure location and not to share/distribute study medication to any other individual; 7. If assigned female sex at birth: 1. Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and over 45 years of age); or (ii) documented surgical sterilization (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or 2. If of childbearing potential, be willing to use an acceptable method of contraception throughout the study and have a negative pregnancy test at screening; 8. Ability to understand and comply with study protocol procedures and to provide written informed consent. Inclusion criteria for Phase 2 In addition to meeting all eligibility criteria outlined in Phase 1, participants will be eligible for Phase 2 provided they meet ALL the following criteria at Week 12: 1. Participants who have not experienced a study medication-related serious adverse event during Phase 1; 2. Participants who have not been lost to follow-up during Phase 1. Exclusion Criteria: 1. Any disabling, severe, or unstable medical or psychiatric condition that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent, as assessed by medical and psychiatric history, physical examination, vital signs, and/or laboratory tests; 2. Any severe or unstable co-morbid substance use disorder (e.g., delirium tremens, acute alcohol intoxication) that, in the opinion of the study physician, precludes safe participation in the study; 3. Currently pregnant or breastfeeding, or planning to become pregnant; 4. Known or suspected allergy or hypersensitivity to cannabinoids; 5. History of respiratory disease, severe cardiovascular, cerebrovascular, renal or liver disease; 6. Current or historic cannabis use disorder; 7. Taking warfarin, clopidogrel, clobazam, theophylline, clozapine and olanzapine medications as they may interact with cannabinoids in a clinically significant manner if they cannot be switched to a different medication; 8. Any personal or family history (first degree relative) of primary psychotic disorders (i.e., schizophrenia, schizoaffective disorder) as per DSM-5 criteria; 9. Unable to abstain from driving any vehicle or operating machinery for at least 10 hours after taking the study medication. In cases where impairment persists beyond the initial 10-hour period, participants must continue to adhere to these restrictions until the impairment resolves; 10. Actively participating in other interventional clinical trial(s); 11. Incarcerated, pending legal action or other reasons that might prevent completion of the study. |
Country | Name | City | State |
---|---|---|---|
Canada | Rapid Access Addiction Clinic (RAAC), St. Paul's Hospital | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
BC Centre on Substance Use | Canadian Institutes of Health Research (CIHR) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Retention in OAT | Retention in OAT will be measured by the proportion of participants on OAT at W12 and at W24, defined as having both a) an active OAT prescription at week 12/24, and b) a positive UDT result for the prescribed OAT at week 12/24. | 24 weeks | |
Other | Illicit opioid use | Suppression of illicit opioid use will be measured as the percentage of opioid-free weeks during W1-12, using a combination of Urine Drug Test (UDT) results and self-reported illicit opioid use assessed by the TLFB. | 24 weeks | |
Other | Pain Intensity | The severity of pain will be assessed by the validated scale within the Patient-Reported Outcomes Measurement Information System (PROMIS) 29+2 Profile v2.1 (PROPr): the PROMIS Pain Intensity item. | 24 weeks | |
Other | Pain Interference | The impact of pain on its impact on functioning will be assessed the validated scale within the Patient-Reported Outcomes Measurement Information System (PROMIS) 29+2 Profile v2.1 (PROPr): PROMIS SF v1.0 - Pain Interference 4a scale. | 24 weeks | |
Other | Anxiety | Anxiety symptoms will be assessed by the validated short scale within the PROMIS 29+2 Profile v2.1 (PROPr): the PROMIS SF v1.0 - Anxiety 4a | 24 weeks | |
Other | Depression | Depressive symptoms will be assessed by the validated short scale within the PROMIS 29+2 Profile v2.1 (PROPr): the PROMIS SF v1.0 - Depression 4a. | 24 weeks | |
Other | Changes in health-related quality of life | Changes in health-related quality of life (HRQoL) between screening and the end of treatment will be measured by the PROMIS 29+2 Profile v2.1 (PROPr). | 24 weeks | |
Other | Changes in substance-use related problems | The Addiction Severity Index (ASI) Self-Report form will be used to assess changes in substance-use related problems between Baseline (W0) prior to the start of treatment administration, Treatment Visit at W12 and EOT (W24)/Early Termination. | 24 weeks | |
Other | Opioid Craving | Opioid craving over time will be measured using a 100-mm visual analog scale (VAS), with 11 lines labeled from left to right with the numbers "0" to "10", and word anchors at each end representing the extremes, where "0=no craving" and "100 mm=most intense craving". | 24 weeks | |
Primary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | The safety will be evaluated by monitoring and gathering information on physical exam, vital signs, pregnancy testing, adverse events (AE) and serious adverse events (SAE), from the screening visit up to the End of Treatment (EOT)/Early Termination visit. AEs and SAEs will be monitored and recorded throughout the study duration. The proportion of participants who experience AEs or SAEs will be assessed by study arm. | 28 weeks | |
Primary | Risk of Treatment Contamination | The proportion of participants using non-study cannabis in the control arm, and proportion of days in Phase 1 where non-study cannabis was used. Self-report of non-study cannabis use will be collected using the Timeline Follow Back (TLFB). | 24 weeks | |
Primary | Participants' adherence to treatment | The degree of compliance with the recommended treatment plan, including study drug dosage and administration. This measures how well participants are able to stick to the prescribed treatment regimen and whether or not they are able to complete the full course of treatment. This will be assessed through a self-reported measure, such as study drug diary or treatment logs. | 24 weeks | |
Primary | Acceptability | Participant satisfaction with the assigned treatment will be assessed through administration of the Medical Safety Questionnaire (MSQ) every 4 weeks during treatment phase The MSQ is a participant-completed questionnaire that evaluates participant satisfaction with study treatment on a 7-point Likert scale. | 24 weeks | |
Primary | Blinding effectiveness | The blinding success questionnaire will be used to evaluate the participants' awareness of their assigned treatment. | 24 weeks | |
Primary | Adequacy of Dose | Patient satisfaction with dose level assessed through the adequacy of dose questionnaire and regular consultations | 24 weeks | |
Secondary | The number of potential participants referred to the study | 24 weeks | ||
Secondary | The screening failure rates | 24 weeks | ||
Secondary | The monthly enrolment rates | 24 weeks | ||
Secondary | The proportion of eligible participants who are willing to be randomized, willing to initiate the intervention and willing to complete 12-week assessments by study arm | 24 weeks | ||
Secondary | The proportion of scheduled study visits completed by study arm | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06021431 -
Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT
|
N/A | |
Completed |
NCT06266572 -
Overcoming Stigma and Improving Outcomes for SUDs Through Education, Engagement, and Empowerment
|
Phase 1 | |
Recruiting |
NCT05037682 -
Pain and Opioid Management in Older Adults
|
N/A | |
Completed |
NCT06200740 -
Remotely Observed Methadone Evaluation
|
N/A | |
Not yet recruiting |
NCT06441604 -
Extended-release Buprenorphine as a Novel Low-dose Induction Strategy
|
Phase 2 | |
Recruiting |
NCT06028126 -
Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial
|
N/A | |
Completed |
NCT02593474 -
Medication-Assisted Treatment for Youth With Substance Use Disorders
|
Phase 1 | |
Completed |
NCT02440256 -
Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial
|
N/A | |
Completed |
NCT02559973 -
Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder
|
Phase 1 | |
Completed |
NCT05587998 -
A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
|
Phase 1 | |
Terminated |
NCT04577144 -
An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term
|
||
Recruiting |
NCT06001437 -
Following Outcomes Remotely Within Addiction Recovery Domains
|
||
Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 | |
Completed |
NCT05546229 -
Assessment of Methadone and Buprenorphine in Interstitial Fluid
|
||
Not yet recruiting |
NCT06104280 -
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
|
N/A | |
Not yet recruiting |
NCT06416020 -
Integrating MOUD in African American Community Settings (Better Together)
|
N/A | |
Recruiting |
NCT06206291 -
Cannabidiol for Opioid Addiction
|
Phase 2 | |
Completed |
NCT05552040 -
START NOW in the Treatment of Opioid Addicted Individuals
|
N/A | |
Recruiting |
NCT05459922 -
Adjunctive Bright Light Therapy for Opioid Use Disorder
|
N/A | |
Recruiting |
NCT05343169 -
Community-based Education, Navigation, and Support Intervention for Military Veterans
|
N/A |